Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Durvalumab

Therapy optimization remains an important challenge in the treatment of advanced non‐small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters (SLD) of target lesions) and neutrophil‐to‐lymphocyte ratio (NLR) as longitudinal biomarkers for survival prediction. Data set...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavrilov, Sergey, Zhudenkov, Kirill, Helmlinger, Gabriel, Dunyak, James, Peskov, Kirill, Aksenov, Sergey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825193/
https://www.ncbi.nlm.nih.gov/pubmed/33319498
http://dx.doi.org/10.1002/psp4.12578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825193/
https://www.ncbi.nlm.nih.gov/pubmed/33319498
http://dx.doi.org/10.1002/psp4.12578

Ejemplares similares